Afinitor Clinical Trials
Here are the 6 most popular medical studies for afinitor
Everolimus + Letrozole for Ovarian Cancer
This trial is testing if the combination of everolimus (Afinitor®) and letrozole is effective in the treatment of women with either recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal or endometrial cancer.
Vandetanib + Everolimus for Cancer
This trial is testing the side effects and best dose of two drugs when given together to treat patients with cancer that has spread. The drugs may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Lutetium Lu 177 Dotatate for Bronchial Neuroendocrine Tumors
This trial compares lutetium Lu 177 dotatate to the usual treatment, everolimus, for patients with neuroendocrine tumors that have spread to other parts of the body. Lutetium Lu 177 dotatate may be more effective than everolimus and cause less harm to normal cells.
Phase 3 Clinical Trials
View 78 phase 3 medical studies.
Selective Estrogen Receptor Degrader (SERD)
Giredestrant + Everolimus for Breast Cancer
This trial will compare two cancer treatments to see which is more effective in treating breast cancer that is Advanced or has Metastasized and is estrogen receptor and human epidermal growth factor receptor 2 positive.
Clinical Trials With No Placebo
View 78 medical studies that do not have a placebo group.
Tyrosine Kinase Inhibitor
Combination Therapy with Neratinib and Everolimus, Palbociclib, or Trametinib for Solid Tumors with Specific Genetic Mutations
This trial is testing neratinib in combination with everolimus, palbociclib, or trametinib to see if it is effective in treating solid tumors that have progressed despite prior treatment and have spread to other parts of the body.
View More Afinitor Trials
See another 59 many medical studies focused on afinitor.
Doxorubicin, Abiraterone, Bevacizumab, Nivolumab, Sunitinib, Tretinoin, Entrectinib, Losartan, Pembrolizumab, Sorafenib, Vemurafenib, Vismodegib, Abemaciclib, Bortezomib, Afatinib, Cobimetinib, Carboplatin, Darolutamide, Olaparib, Cabozantinib, Ponatinib, Cabazitaxel, Dabrafenib, Idelalisib, Oxaliplatin, Palbociclib, Erlotinib, Pertuzumab, Ruxolitinib, Trametinib, Bicalutamide, Dasatinib, Nab-paclitaxel, Neratinib, Fluorouracil, Capecitabine, Sirolimus, Durvalumab, Enasidenib, Everolimus, Leucovorin, Regorafenib, Dacomitinib, Imatinib, Trastuzumab Emtansine, Venetoclax, Ipilimumab, Lenvatinib, Lorlatinib, Celecoxib, Copanlisib, Vorinostat